Gauhar Hussain1, S Aijaz Abbas Rizvi2, Sangeeta Singhal2, Mohammad Zubair3, Jamal Ahmad4. 1. Department of Physiology, Teerthankar Mahaveer Medical College & Research Centre, Teerthankar Mahaveer University, Moradabad, U.P., India. 2. Department of Physiology, J.N. Medical College & Hospital, Aligarh Muslim University, Aligarh, U.P., India. 3. Rajiv Gandhi Centre for Diabetes and Endocrinology, J.N. Medical College & Hospital, Aligarh Muslim University, Aligarh 202002, U.P., India. 4. Rajiv Gandhi Centre for Diabetes and Endocrinology, J.N. Medical College & Hospital, Aligarh Muslim University, Aligarh 202002, U.P., India. Electronic address: jamalahmad11@rediffmail.com.
Abstract
AIMS: To correlate serum levels of TGF-β1 with motor and sensory nerve conduction velocities in patients of type 2 diabetes mellitus MATERIALS AND METHODS: The study was conducted in diagnosed type 2 diabetes mellitus patients which were divided in patients with clinically detectable peripheral neuropathy of shorter duration (n=37) and longer duration (n=27). They were compared with patients without clinical neuropathy (n=22). Clinical diagnosis was based on neuropathy symptom score (NSS) and Neuropathy disability score (NDS) for signs. Blood samples were collected for baseline investigations and estimation of serum TGF-β1. Nerve conduction velocity was measured in both upper and lower limbs. Median, Ulnar, Common Peroneal and Posterior Tibial nerves were selected for motor nerve conduction study and Median and Sural nerves were selected for sensory nerve conduction study RESULTS: In patients of type 2 diabetes mellitus with clinically detectable and serum TGF-β1 showed positive correlation with nerve conduction velocities CONCLUSION: High level of TGF-β1 in serum of T2DM patients with neuropathy show possible contribution in development of neuropathy. Due to its independent association this cytokine might be used as biomarker for diabetic peripheral neuropathy.
AIMS: To correlate serum levels of TGF-β1 with motor and sensory nerve conduction velocities in patients of type 2 diabetes mellitus MATERIALS AND METHODS: The study was conducted in diagnosed type 2 diabetes mellituspatients which were divided in patients with clinically detectable peripheral neuropathy of shorter duration (n=37) and longer duration (n=27). They were compared with patients without clinical neuropathy (n=22). Clinical diagnosis was based on neuropathy symptom score (NSS) and Neuropathy disability score (NDS) for signs. Blood samples were collected for baseline investigations and estimation of serum TGF-β1. Nerve conduction velocity was measured in both upper and lower limbs. Median, Ulnar, Common Peroneal and Posterior Tibial nerves were selected for motor nerve conduction study and Median and Sural nerves were selected for sensory nerve conduction study RESULTS: In patients of type 2 diabetes mellitus with clinically detectable and serum TGF-β1 showed positive correlation with nerve conduction velocities CONCLUSION: High level of TGF-β1 in serum of T2DM patients with neuropathy show possible contribution in development of neuropathy. Due to its independent association this cytokine might be used as biomarker for diabetic peripheral neuropathy.
Authors: Dan Ziegler; Alexander Strom; Gidon J Bönhof; Julia M Kannenberg; Margit Heier; Wolfgang Rathmann; Annette Peters; Christina Meisinger; Michael Roden; Barbara Thorand; Christian Herder Journal: BMJ Open Diabetes Res Care Date: 2019-11-27